KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Receivables (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Receivables for 16 consecutive years, with $777.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 91.85% year-over-year to $777.6 million, compared with a TTM value of $777.6 million through Dec 2025, up 91.85%, and an annual FY2025 reading of $777.6 million, up 91.85% over the prior year.
  • Receivables was $777.6 million for Q4 2025 at Alnylam Pharmaceuticals, down from $964.8 million in the prior quarter.
  • Across five years, Receivables topped out at $964.8 million in Q3 2025 and bottomed at $9.1 million in Q2 2022.
  • Average Receivables over 5 years is $329.5 million, with a median of $315.4 million recorded in 2024.
  • The sharpest move saw Receivables skyrocketed 5312.39% in 2021, then tumbled 98.3% in 2022.
  • Year by year, Receivables stood at $73.3 million in 2021, then crashed by 55.86% to $32.3 million in 2022, then surged by 207.88% to $99.6 million in 2023, then surged by 307.03% to $405.3 million in 2024, then surged by 91.85% to $777.6 million in 2025.
  • Business Quant data shows Receivables for ALNY at $777.6 million in Q4 2025, $964.8 million in Q3 2025, and $567.1 million in Q2 2025.